The SHIVA01 trial: what have we learned?

Pharmacogenomics. 2017 Jun;18(9):831-834. doi: 10.2217/pgs-2017-0062. Epub 2017 Jun 8.
No abstract available

Keywords: SHIVA01; biomarker; cancer; precision medicine; trial design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Precision Medicine / methods
  • Signal Transduction / drug effects*
  • Signal Transduction / genetics

Substances

  • Antineoplastic Agents